severe primary axillary hyperhidrosis
Dermatology · 2010–2010
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| botulinum toxin type A purified neurotoxin complex Treatment of severe primary axillary hyperhidrosis in adolescent and adult patients (12 years or older) who have failed or are intolerant to topical aluminium… | Mar 2010 | Recommended with restriction | no section in document |
| botulinum toxin type A purified neurotoxin complex Treatment of severe primary axillary hyperhidrosis in adolescent and adult patients (≥12 years) who have failed or are intolerant to topical aluminium chloride… | Mar 2010 | Recommended with restriction | no section in document |
What the PBS pays
$73M in government benefit over 2024–25, across 140,782 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| botulinum toxin type A | $72.8M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.